Table 1 Baseline characteristics according to second-line therapy in addition to metformin

15,426 (33%)

13,148 (28%)

2343 (5%)

8917 (19%)

7152 (15%)

9160 (59%)

7403 (56%)^b

1398 (60%)

5473 (61%)

4480 (63%)^b

62.4 (± 11.9)

58.0 (± 11.2)

60.2 (± 11.3)

59.6 (± 12.0)

61.2 (± 13.2)

< 0.0001

5.1 (± 4.0) 

 6.5 (± 4.5)

 7.2 (± 5.1)

3.0 (± 3.0) 

4.7 (± 4.4) 

< 0.0001

1.8 (± 0.4)

1.9 (± 0.3)

1.4 (± 0.6)

1.8 (± 0.4)

1.7 (± 0.5)

< 0.0001

11,370 (74%)

8423 (64%)^b

1489 (64%)^b

7401 (83%)^b

5007 (70%)^b

1461 (9%)

2157 (16%)^b

563 (24%)^b

233 (3%)^b

758 (11%)

2595 (17%)

2568 (20%)^b

291 (12%)^b

1283 (14%)^b

1387 (19%)^b

945 (6%)

920 (7%)

113 (5%)

568 (6%)

652 (9%)^b

6145 (40%)

6523 (50%)^b

841 (36%)^b

3162 (35%)^b

3160 (44%)^b

1409 (9%)

1106 (8%)

121(5%)^b

757 (8%)

741 (10%)

2125 (14%)

1630 (12%)^b

232 (10%)^b

1133 (13%)

1373 (19%)^b

356 (2%)

386 (3%)

57 (2%)

183 (2%)

194 (3%)

1245 (8%)

1390 (11%)^b

109 (5%)^b

477 (5%)^b

772 (11%)^b

1993 (13%)

2089 (16%)^b

249 (11%)^b

1013 (11%)^b

1008 (14%)

378 (2%)

384 (3%)

37 (2%)

175 (2%)

290 (4%)

10,902 (71%)

11,758 (89%)^b

1477 (63%)^b

6139 (69%)

4648 (65%)^b

9630 (62%)

9120 (69%)^b

1277 (55%)^b

5458 (61%)

4284 (60%)^b

933 (6%)

1201 (9%)^b

90 (4%)^b

546 (6%)

628 (9%)^b

3096 (20%)

3173 (24%)^b

304 (13%)^b

1797 (20%)

1484 (21%)

5354 (35%)

5389 (41%)^b

622 (27%)^b

2973 (33%)

2460 (34%)

4276 (28%)

4076 (31%)^b

503 (21%)^b

2332 (26%)

1961 (27%)

1048 (7%)

988 (8%)

101 (4%)^b

521 (6%)

531 (7%)

567 (4%)

370 (3%)^b

30 (1%)^b

317 (4%)

335 (5%)

5472 (35%)

5942 (45%)^b

645 (28%)^b

2844 (32%)

2623 (37%)^b

2739 (18%)

3162 (24%)^b

259 (11%)^b

1458 (16%)

1728 (24%)^b